IGF-1 LR3

Plain-English version: Your liver makes a hormone called IGF-1 whenever growth hormone tells it to. IGF-1 is the messenger that actually carries out much of growth hormone's work — building muscle, maintaining bone, and repairing tissue. IGF-1 LR3 is a laboratory redesign of that natural messenger, tweaked so it lasts much longer and pushes much harder.

Native IGF-1 is a 70-amino-acid protein. In the body it barely gets to act on its own: roughly 98% of it is immediately grabbed by six carrier proteins called IGF-binding proteins (IGFBP-1 through IGFBP-6), which hold it in reserve and control when and where it works. Free, unbound native IGF-1 is cleared within about 12-15 minutes. That tight regulation is a feature of your biology — and the exact thing IGF-1 LR3 was built to defeat.

The name decodes the engineering. "R3" means an arginine substituted at position 3 (replacing the native glutamic acid). "L" (Long) means a 13-amino-acid extension added to the N-terminus. Francis and colleagues, who first built and characterized LongR3-IGF-I in 1992, showed these changes make the analogue bind the IGF-binding proteins very poorly. Critically, they demonstrated that the enhanced biological potency comes from this reduced IGFBP binding, not from any increase in receptor affinity — the molecule does not grip the receptor harder, it simply escapes the proteins that would have sidelined it.^[1] With the carrier proteins out of the picture, far more active IGF-1 stays in circulation, and the half-life stretches to roughly 20-30 hours.

IGF-1 LR3 was originally created as a research tool — a way to study IGF-1 signaling without the confounding influence of the binding proteins — and it remains a standard supplement in serum-free cell culture media. It was never developed for clinical use and has no regulatory approval in any country. Do not confuse it with mecasermin (brand name Increlex), the only FDA-approved recombinant human IGF-1: that product is native, unmodified rhIGF-1 approved narrowly for severe primary IGF-1 deficiency and for IGF-1 gene deletion with growth-hormone antibodies. IGF-1 LR3 is a different molecule and has never been submitted for approval.

Takeaway first: IGF-1 LR3 works by doing exactly what native IGF-1 does at the receptor — but because it dodges the binding proteins, much more of it reaches the receptor and it keeps signaling for hours instead of minutes. The receptor it hits, the IGF-1 receptor (IGF-1R), fires the body's central growth-and-repair pathways.

1. It evades the binding proteins (the whole point)

This is the mechanism that defines the molecule. Native IGF-1 spends most of its life bound and inert; LR3, by design, does not. Francis et al. established that the analogue's ~100-fold weaker IGFBP binding — not tighter receptor grip — is what produces its greater potency in rat L6 myoblast (muscle-cell) assays.^[1] Everything downstream is native IGF-1 signaling, just amplified because more free ligand is present for longer. Evidence level: in vitro plus rat cells.

2. PI3K/Akt/mTOR — the anabolic pathway

When IGF-1 (or LR3) binds IGF-1R, the receptor phosphorylates IRS-1, which switches on PI3K, then Akt, then mTOR. This cascade is the master "build" signal in muscle: it ramps up protein synthesis (through S6K1 and 4E-BP1) and, at the same time, suppresses protein breakdown by keeping FOXO transcription factors out of the cell nucleus, which shuts down the muscle-wasting ubiquitin-proteasome system. This is standard, well-mapped IGF-1 biology and the mechanistic reason IGF-1 signaling is anti-catabolic (muscle-sparing). A review by Clemmons summarizes IGF-I's role in maintaining muscle mass and preventing atrophy through these pathways.^[6] Evidence level: established signaling biology / review, not LR3-specific human data.

3. Satellite-cell activation — the basis of the "hyperplasia" idea

IGF-1 signaling promotes the proliferation and differentiation of satellite cells, the muscle's resident stem cells. In transgenic mice, a locally expressed IGF-1 isoform sustained muscle hypertrophy and preserved the regenerative capacity of aged muscle.^[5] This is the mechanistic seed for the popular claim that IGF-1 LR3 causes muscle hyperplasia (new muscle fibers, not just bigger ones). Read that carefully: the mouse study used an IGF-1 transgene, not LR3, and hyperplasia has never been demonstrated in humans from any IGF-1 product. Treat hyperplasia as a mechanistic hypothesis, not a proven LR3 effect. Evidence level: transgenic mice.

4. Insulin-like metabolic effects (and why hypoglycemia happens)

IGF-1 is structurally related to insulin, and at meaningful concentrations it drives glucose out of the blood and into cells — partly through its own receptor and partly by cross-reacting with the insulin receptor and hybrid IGF-1R/insulin receptors. Because LR3 keeps far more free ligand in circulation for far longer, this glucose-lowering effect is both stronger and more prolonged than with native IGF-1. This is not a fringe worry: it is the single best-documented in-vivo effect of LR3 and is covered in detail in the safety section.^[3]

What we do NOT know

There is no human pharmacokinetic data for IGF-1 LR3 (how it is absorbed, distributed, and cleared in people), no human dose-response data, and no controlled human outcome of any kind. The pathways above are real and well-understood for IGF-1 signaling in general, but "the receptor exists and the pathway works" is not the same as "this injected analogue safely builds muscle in humans." That leap has never been tested.

How to read this section: for each area we give the plain-English claim, the proposed mechanism, the population actually studied, the observed effect, and the limitation. The honest headline is stark — there is not a single human study of IGF-1 LR3, so every "benefit" below is either an animal/cell finding or a mechanistic extrapolation. That does not make it worthless; it makes it preliminary.

Greater potency than native IGF-1

Claim: LR3 does more per molecule than native IGF-1. Mechanism: it evades IGFBP sequestration, leaving more free ligand active. Population: rat L6 myoblasts in vitro (Francis) and normal plus catabolic rats in vivo (Tomas). Effect: Francis et al. showed the analogue's enhanced biological potency in muscle-cell assays traced entirely to reduced binding-protein affinity.^[1] Tomas et al. then showed this superior anabolic and anti-catabolic potency was maintained when the analogue was given by subcutaneous injection — not just by continuous infusion — in normal rats and in a dexamethasone-induced catabolic (muscle-wasting) rat model.^[2] Limitation: rodent and cell data only; "more potent than native IGF-1" is a comparison between two research compounds, not evidence of a human benefit.

Muscle growth and preservation

Claim: may build muscle and protect it from wasting. Mechanism: PI3K/Akt/mTOR-driven protein synthesis plus FOXO-mediated suppression of breakdown. Population: transgenic mice (IGF-1 isoform) and catabolic rats. Effect: localized IGF-1 transgene expression sustained hypertrophy and regeneration in aged mouse muscle,^[5] and LR3 retained anti-catabolic potency in the glucocorticoid-wasting rat model.^[2] A review confirms IGF-I's central role in maintaining muscle mass.^[6] Limitation: the strongest hypertrophy evidence used an IGF-1 transgene, not injected LR3; there is no human muscle-growth trial of LR3, and the widely repeated "hyperplasia builds new fibers in humans" claim is unproven in any species outside genetic models.

Nutrient partitioning

Claim: drives glucose and amino acids into muscle. Mechanism: insulin-like signaling increases glucose uptake (GLUT4) and amino-acid transport, favoring anabolism. Population: established IGF-1/insulin cell biology; in-vivo glucose lowering measured in pigs and marmosets.^[3] Effect: enhanced cellular nutrient uptake. Limitation: the very same mechanism that "partitions nutrients" is what causes hypoglycemia — the benefit and the hazard are inseparable, and only the hazard has actually been measured in vivo.

Cell culture applications (the one truly established use)

Claim: a superior growth supplement for cultured cells. Mechanism: resistance to IGFBP binding makes its activity predictable in serum-free media. Population: laboratory cell culture. Effect: LR3 is a standard media supplement, typically at 50-100 ng/mL, valued because its potency does not drift as binding proteins accumulate. Limitation: this is a benchtop use, not a therapeutic one — it tells you the molecule is biologically active in a dish, nothing more about human safety or muscle outcomes.

The honest bottom line on "benefits"

• Zero human trials. No randomized or observational study has ever given IGF-1 LR3 to people and measured a result.
• Hyperplasia, organomegaly, and acromegaly-like effects are extrapolations, not documented LR3 outcomes — the mechanism is plausible, the human demonstration does not exist.
• Animal potency does not equal human benefit, and it certainly does not offset an unregulated compound's risks.
• Anecdotes are not data. Bodybuilding-forum reports cannot substitute for controlled trials that were never run.

Read this first: there is no clinically validated human dose for IGF-1 LR3, because no human dosing study has ever been conducted. Every figure below comes from research-community convention and animal work, not trials. We describe them for completeness and harm reduction, not as guidance to use an unapproved compound. IGF-1 LR3 is dosed in micrograms (mcg), not milligrams — a hundred-fold-smaller unit than most peptides — which makes measurement error easy and consequential.

Commonly cited research protocols (extrapolated, not validated)

Protocol	Commonly cited dose	Frequency	Route	Note
Conservative / entry	20-40 mcg	Once daily	Subcutaneous	Lower end to gauge glucose response
Standard research	40-60 mcg	Once daily	Subcutaneous	Long half-life means once-daily is sufficient
Post-training (local)	up to ~100 mcg	Training days	Intramuscular	Aimed at worked muscle; higher hypoglycemia exposure
Cell culture	50-100 ng/mL	Media supplement	In vitro	Benchtop use, not administration

Because the half-life is roughly 20-30 hours, once-daily dosing keeps levels steady — there is no pharmacologic reason to split doses the way short-acting peptides are split.

Reconstitution math, with a worked example

IGF-1 LR3 ships as a lyophilized (freeze-dried) powder that must be reconstituted before use. Suppliers formulate it for either bacteriostatic water or a dilute (~0.6%) acetic acid solution — check which your vial requires, because the wrong solvent can degrade it. The core formula:

Concentration (mcg/mL) = vial amount (mcg) ÷ solvent added (mL)

Worked example: a common vial is 1 mg (1,000 mcg). Add 1 mL of solvent and you get 1,000 ÷ 1 = 1,000 mcg/mL. To draw a 40 mcg dose: 40 ÷ 1,000 = 0.04 mL, which is 4 units on a standard 100-unit insulin syringe. A 50 mcg dose is 0.05 mL, or 5 units. Because each unit is 10 mcg at this concentration, small syringe errors translate into meaningful dose swings — measure carefully.

Vial	Solvent added	Concentration	20 mcg	40 mcg	50 mcg
1 mg	1 mL	1,000 mcg/mL	0.02 mL (2 units)	0.04 mL (4 units)	0.05 mL (5 units)
1 mg	2 mL	500 mcg/mL	0.04 mL (4 units)	0.08 mL (8 units)	0.10 mL (10 units)

Preparation steps: wipe the stopper with alcohol; draw the solvent; inject it slowly down the inside wall of the vial rather than blasting the powder; swirl gently (never shake — IGF-1 LR3 is sensitive to agitation and can denature) until fully dissolved; label the vial with the date and concentration. Use the peptide calculator and bacteriostatic water calculator to check volumes.

Timing, cycles, and the glucose rule

• Cycle length: research protocols commonly run 4-6 weeks. The rationale is convention plus concern that sustained, unregulated IGF-1R activation raises safety risk over time — it is not a trial-derived limit.
• Food timing: because the dominant measured effect is glucose-lowering, protocols pair dosing with a carbohydrate-containing meal to blunt hypoglycemia. This is the most important practical point on the page.
• No loading or taper: no loading dose or taper is described in the literature.

Storage: keep lyophilized vials frozen (around -20°C) for long-term stability. Once reconstituted, refrigerate at 2-8°C and use within about 3-4 weeks; avoid freeze-thaw cycles and never leave it at room temperature. None of the above should be read as a recommendation to self-administer — it is a description of how research doses are structured.

Straight talk: IGF-1 LR3 has one adverse effect that is genuinely well-documented in living animals — prolonged hypoglycemia — and several others that are biologically plausible but not demonstrated for LR3 specifically. There are no controlled human safety studies at all, so most of what follows is mechanism and animal data, not human evidence. A separate, underappreciated hazard is product quality: unregulated vials vary widely, and contaminants can cause effects blamed on the peptide.

Hypoglycemia — the documented, serious risk

This is the standout. Tomas, Walton, Dunshea and Ballard directly measured that LR3-IGF-I and other low-IGFBP-affinity variants were 2-3 times more potent than native IGF-1 at lowering plasma glucose, and — because they persist in circulation — produced hypoglycemia that lasted far longer, on the order of 4-8 times greater total hypoglycemic effect, in pigs and marmoset monkeys.^[3] In plain terms: the very feature that makes LR3 "better" (escaping the binding proteins) also makes its blood-sugar crash deeper and much longer-lasting. Symptoms of hypoglycemia include shakiness, sweating, hunger, confusion, and — if severe — loss of consciousness or seizure. This is why every protocol insists on eating carbohydrates around dosing and having fast-acting glucose on hand.

IGF-1 pathway and cancer risk — a real but indirect concern

IGF-1 signaling drives cell proliferation, which raises an obvious question about cancer. A large human meta-analysis by Renehan et al. found that high circulating IGF-1 is associated with increased risk of prostate cancer and premenopausal breast cancer.^[4] Read the limits of that carefully: it studied people's own endogenous IGF-1 levels, not injected LR3, so it establishes a mechanistic and epidemiologic concern — not proof that LR3 causes cancer. Still, injecting a potent, long-acting IGF-1R agonist is exactly the kind of exposure that concern is about, which is why anyone with a personal or family history of cancer is universally advised to avoid it.

Theoretical growth-related effects (extrapolated, not shown for LR3)

• Organ growth (organomegaly): chronic IGF-1R activation can, in principle, enlarge internal organs such as the intestines, heart, and kidneys — the mechanism behind acromegalic organomegaly. This has not been demonstrated for LR3 specifically; treat it as a theoretical risk of sustained signaling.
• Acromegaly-like changes: jaw, hand, and foot growth with prolonged excess IGF-1 is a recognized clinical picture in disease states, and is extrapolated to chronic LR3 use — again, not documented for LR3.
• Water retention and joint pain: commonly reported with growth-axis manipulation generally; plausible here, unquantified for LR3.
• Injection-site reactions: localized redness, swelling, or pain, typical of any subcutaneous or intramuscular injection.

Who should not use it

• Anyone with active or prior cancer, given the proliferative pathway and epidemiologic association.^[4]
• People with diabetes or a tendency toward low blood sugar, because of the documented, prolonged hypoglycemia.^[3]
• Anyone with acromegaly or a growth disorder.
• Pregnant or breastfeeding individuals — no reproductive-safety data exist.

The limitations you must keep in mind

• The favorable-sounding data are potency comparisons, not safety clearances; the clearest in-vivo signal is an adverse one (hypoglycemia).
• No human trials means human pharmacokinetics, drug interactions, and long-term safety are entirely unknown.
• For context, mecasermin (Increlex), the approved native rhIGF-1, carries labeled warnings including hypoglycemia and intracranial hypertension even under medical supervision — LR3 is more potent, longer-acting, and used with none of that oversight.

For broader context, see Are Peptides Safe? and Peptide Side Effects.

Why this section matters: IGF-1 LR3 is an unregulated research protein sold in tiny quantities, and purity, identity, and biological activity vary enormously between suppliers. For a compound this potent and this poorly characterized in humans, a contaminated or misidentified vial is a serious hazard on top of the drug's own risks. Learning to read a Certificate of Analysis (COA) is the most useful protective skill.

What a credible product should show

• Third-party COA: independent HPLC purity testing (look for ≥98%) plus mass-spectrometry identity confirming the expected molecular weight of the LR3 analogue (~9,100 Da — note this is far larger than short peptides because of the IGF-1 protein backbone plus the N-terminal extension).
• Batch-specific results: the COA should reference the exact lot you are buying, not a generic sample.
• Endotoxin testing (LAL): important for anything intended to be injected.
• Proper form and packaging: lyophilized powder in a sealed, light-protected vial, shipped cold where possible — this is a fragile protein, not a rugged small peptide.

Red flags

• No COA, or a COA from the seller rather than an independent lab
• Pre-mixed "ready to use" liquid (a protein this fragile degrades in solution; short shelf life and contamination risk)
• Prices far below market — real IGF-1 LR3 is expensive to manufacture
• Explicit human-use or dosing claims, which signal a non-compliant, higher-risk vendor

Legal and regulatory status (2026)

• Not FDA-approved for any use, in any country. IGF-1 LR3 has never been submitted for or granted approval, and it is not a dietary supplement.
• The only approved recombinant IGF-1 is mecasermin (Increlex), which is native, unmodified rhIGF-1 — a different molecule — approved narrowly for severe primary IGF-1 deficiency and for IGF-1 gene deletion with GH antibodies, and it carries labeled warnings including hypoglycemia and intracranial hypertension.
• Research-only: IGF-1 LR3 is sold strictly as a research chemical; it is not characterized or regulated for human administration.
• Sports: IGF-1 and its analogues are prohibited by anti-doping authorities, so competitive athletes should treat it as bannable.

For the complete legal picture, read Are Peptides Legal?

IGF-1 LR3 is usually weighed against other ways of pushing the growth axis. None of these comparisons rest on head-to-head human trials — they contrast proposed mechanisms and the animal literature.

Compound	Pathway	Mechanism	Key distinction
IGF-1 LR3	Direct IGF-1R	Long-acting exogenous IGF-1R activation	Most potent; bypasses the GH axis and its feedback entirely
MGF	Local IGF-1 splice variant	Satellite-cell activation near an injury	Local, short-acting repair signal
Ipamorelin + CJC-1295	GH → liver IGF-1	Stimulate the body's own GH and IGF-1	Physiological; keeps natural feedback brakes intact
Mecasermin (Increlex)	Direct IGF-1R	Recombinant native rhIGF-1	FDA-approved for severe IGF-1 deficiency; short-acting

The central trade-off: GH secretagogues work through your own regulated system, so a feedback loop can dial things back. IGF-1 LR3 delivers direct, long-lasting, unregulated receptor activation — more potent per dose, but with none of the biological safety valves, which is precisely why its documented downside (prolonged hypoglycemia) is easy to trigger.

IGF-1 LR3 vs. DES(1-3) IGF-1

DES(1-3) IGF-1 is another modified variant that also binds the IGFBPs poorly (it lacks the first three N-terminal amino acids). The practical difference is duration: DES is short-acting (roughly 20-30 minutes), so it is sometimes favored for localized intramuscular use, while LR3's long half-life suits systemic subcutaneous dosing. Both share the same fundamental risk profile because both work by escaping binding-protein regulation.